Should I buy or sell Molecular Partners stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares. View MOLN analyst ratings or view top-rated stocks .

What is Molecular Partners' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Molecular Partners' shares. Their MOLN share price targets range from $4.50 to $4.50. On average, they expect the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View analysts price targets for MOLN or view top-rated stocks among Wall Street analysts .

How have MOLN shares performed in 2024?

Molecular Partners' stock was trading at $4.18 at the beginning of 2024. Since then, MOLN stock has decreased by 6.5% and is now trading at $3.91. View the best growth stocks for 2024 here .

When is Molecular Partners' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MOLN earnings forecast .

How were Molecular Partners' earnings last quarter?

Molecular Partners AG (NASDAQ:MOLN) issued its earnings results on Thursday, March, 14th. The company reported ($0.68) earnings per share for the quarter. The firm earned $1.17 million during the quarter. Molecular Partners had a negative trailing twelve-month return on equity of 31.10% and a negative net margin of 885.11%.

When did Molecular Partners IPO?

Molecular Partners (MOLN) raised $81 million in an initial public offering on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MOLN

Molecular Partners (MOLN) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free MOLN Stock Alerts

$3.91

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $3.91
▼
$3.91
50-Day Range: $3.73
▼
$4.84
52-Week Range: $3.35
▼
$7.32

Volume: 280 shs
Average Volume: 4,641 shs
Market Capitalization: $142.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Get Molecular Partners alerts:

Molecular Partners MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 15.1% Upside
$4.50 Price Target
Short Interest: Healthy
0.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.96) to ($1.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.64 out of 5 stars

Medical Sector

878th out of 913 stocks

Biological Products, Except Diagnostic Industry

151st out of 153 stocks

2.0

Analyst's Opinion

Consensus Rating
Molecular Partners has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Molecular Partners has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.13% of the outstanding shares of Molecular Partners have been sold short.
Short Interest Ratio / Days to Cover
Molecular Partners has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Molecular Partners has recently decreased by 2.24%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Molecular Partners does not currently pay a dividend.
Dividend Growth
Molecular Partners does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MOLN.

1.8

News and Social Media Coverage

News Sentiment
Molecular Partners has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Molecular Partners this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Molecular Partners insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.93% of the stock of Molecular Partners is held by insiders.
Percentage Held by Institutions
Only 26.55% of the stock of Molecular Partners is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Molecular Partners are expected to grow in the coming year, from ($1.96) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Molecular Partners is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Molecular Partners is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Molecular Partners has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Molecular Partners Stock (NASDAQ:MOLN)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

MOLN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MOLN Stock News Headlines

April 18, 2024 | finance.yahoo.com

We Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth Carefully

April 17, 2024 | globenewswire.com

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | bizjournals.com

Beyond Benign, MilliporeSigma partner on green chemistry

March 26, 2024 | globenewswire.com

Molecular Partners Publishes Invitation to Annual General Meeting 2024

March 21, 2024 | markets.businessinsider.com

Leerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)

March 14, 2024 | globenewswire.com

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

March 13, 2024 | markets.businessinsider.com

Molecular Partners AG (spons. ADRs) hosts conference call for investors

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 13, 2024 | finance.yahoo.com

The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable

March 2, 2024 | uk.investing.com

Molecular Partners wins dismissal of securities lawsuit

March 1, 2024 | globenewswire.com

Molecular Partners Announces Dismissal of Class Action Lawsuit

March 1, 2024 | globenewswire.com

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

January 7, 2024 | finance.yahoo.com

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

January 5, 2024 | msn.com

Molecular Partners, Orano to collaborate on RDT therapies for cancer

December 31, 2023 | ca.finance.yahoo.com

Molecular Partners AG (6ML0.MU)

December 10, 2023 | finance.yahoo.com

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

November 11, 2023 | morningstar.com

Molecular Partners AG ADR MOLN

November 2, 2023 | finance.yahoo.com

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

November 1, 2023 | finance.yahoo.com

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

October 5, 2023 | finance.yahoo.com

Shareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years ago

August 24, 2023 | finance.yahoo.com

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

July 13, 2023 | finance.yahoo.com

Owning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN),

June 27, 2023 | finance.yahoo.com

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

June 27, 2023 | finance.yahoo.com

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

June 19, 2023 | finance.yahoo.com

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

June 2, 2023 | finance.yahoo.com

Companies Like Molecular Partners (VTX:MOLN) Are In A Position To Invest In Growth

See More Headlines

Receive MOLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:MOLN
CUSIP: N/A
CIK: 1745114
Web: www.molecularpartners.com
Phone: 41-44-755-7700
Fax: N/A
Employees: 167
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.50
High Stock Price Target: $4.50
Low Stock Price Target: $4.50
Potential Upside/Downside: +15.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,040,000.00
Net Margins: -885.11%
Pretax Margin: -880.66%
Return on Equity: -31.10%
Return on Assets: -27.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.35
Quick Ratio: 13.35

Sales & Book Value

Annual Sales: $7.84 million
Price / Sales: 18.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.41 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 36,370,000
Free Float: 34,212,000
Market Cap: $142.21 million
Optionable: Not Optionable
Beta: 0.77

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Patrick Amstutz Ph.D. (Age 49)
Co-Founder, CEO, Member of Management Board & Director
Comp: $735.87k
Dr. Michael Tobias Stumpp Ph.D. (Age 52)
Co-Founder, Executive VP of Projects & Member of Management Board
Mr. Robert Hendriks
Senior VP of Finance
Mr. Alexander Zurcher (Age 49)
COO & Member of Management Board
Ms. Renate Gloggner (Age 54)
Executive VP of People & Community and Member of Management Board
Mr. Daniel Steiner Ph.D.
Senior Vice President of Research
Mr. Seth D. Lewis
Senior Vice President of Investor Relations, Communications & Strategy
Mr. Michael Pitzner
General Counsel, Compliance Officer, Senior VP Legal & Business Development
Dr. Pamela A. Trail Ph.D. (Age 68)
Strategic Consultant
Ms. Anne Goubier D.V.M.
Ph.D., Senior Vice President of Biology

Key Competitors

View All Competitors

MOLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Molecular Partners stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares.
View MOLN analyst ratings or view top-rated stocks.
What is Molecular Partners' stock price target for 2024?: 1 Wall Street research analysts have issued twelve-month target prices for Molecular Partners' shares. Their MOLN share price targets range from $4.50 to $4.50. On average, they expect the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for MOLN or view top-rated stocks among Wall Street analysts.
How have MOLN shares performed in 2024?: Molecular Partners' stock was trading at $4.18 at the beginning of 2024. Since then, MOLN stock has decreased by 6.5% and is now trading at $3.91.
View the best growth stocks for 2024 here.
When is Molecular Partners' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MOLN earnings forecast.

How were Molecular Partners' earnings last quarter?: Molecular Partners AG (NASDAQ:MOLN) issued its earnings results on Thursday, March, 14th. The company reported ($0.68) earnings per share for the quarter. The firm earned $1.17 million during the quarter. Molecular Partners had a negative trailing twelve-month return on equity of 31.10% and a negative net margin of 885.11%.
When did Molecular Partners IPO?: Molecular Partners (MOLN) raised $81 million in an initial public offering on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.
How do I buy shares of Molecular Partners?: Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOLN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial